| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -318.4% | -964.0% |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 25.0 | 111.3 |
| Pr/Book | n/a |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | -100.0% |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Apr-21 | n/a | (16.81) | (2.28)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Apr-22 | n/a | (6.27) | (0.56)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Apr-23 | 5.27 | (14.30) | (1.50)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Apr-24 | n/a | (9.12) | (0.68)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Apr-25 | 4.71 | (15.30) | (1.26)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Holding(s) in Company | 31-Jul-2026 | 17:32 | RNS |
| Extension of Option Exercise Period | 31-Jul-2026 | 07:00 | RNS |
| Holding(s) in Company | 28-Jul-2026 | 15:40 | RNS |
| /C O R R E C T I O N -- KushoAI/ | 02-Apr-2026 | ShareCast |
| FDA clears Scancell's application for phase thre... | 26-Jan-2026 | ShareCast |
| Scancell reports further data from DNA cancer im... | 09-Dec-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 9.75p |
| Change Today | -0.050p |
| % Change | -0.51 % |
| 52 Week High | 26.25 |
| 52 Week Low | 8.54 |
| Volume | 2,099,398 |
| Shares Issued | 1,212.23m |
| Market Cap | £118.19m |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:36 | 79,468 @ 9.79p |
| 16:35 | 184,000 @ 9.80p |
| 16:15 | 1,152 @ 9.77p |
| 16:09 | 8,607 @ 9.77p |
| 15:59 | 1,567 @ 9.77p |
| CFO | Sath Nirmalananthan |
| CEO | Phil L'Huillier |
You are here: research